Andrew Perry, Chief Commercial Officer at G1 Therapeutics, Inc. (GTHX), sold 355 shares at $2.45 ($870) on 2023-07-05, disclosed to the SEC on 2023-07-07.
Scheduled sale ($870) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| GTHX | SELL | 2024-01-08 | $8K | — | Filing → |
| GTHX | SELL | 2023-01-05 | $5K | — | Filing → |